These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 30744560)

  • 1. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
    Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
    BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
    Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
    PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
    Guy CD; Suzuki A; Abdelmalek MF; Burchette JL; Diehl AM;
    Hepatology; 2015 Jan; 61(1):98-107. PubMed ID: 24849310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Interplay Between Sonic Hedgehog and Transforming Growth Factor-β1 in Human Nonalcoholic Steatohepatitis.
    Zhou X; Wang P; Ma Z; Li M; Teng X; Sun L; Wan G; Li Y; Guo L; Liu H
    Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):154-160. PubMed ID: 32044884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers.
    Shen J; Chan HL; Wong GL; Chan AW; Choi PC; Chan HY; Chim AM; Yeung DK; Yu J; Chu WC; Wong VW
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1057-66. PubMed ID: 23066946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: A systematic review and meta-analysis.
    Lee J; Vali Y; Boursier J; Duffin K; Verheij J; Brosnan MJ; Zwinderman K; Anstee QM; Bossuyt PM; Zafarmand MH
    PLoS One; 2020; 15(9):e0238717. PubMed ID: 32915852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of serum M30 and M65 in chronic hepatitis B patients with non-alcoholic fatty liver disease.
    Liang J; Han T; Gao YT; Jing L; Ma Z
    Eur Rev Med Pharmacol Sci; 2015 Nov; 19(21):4123-9. PubMed ID: 26592838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease.
    Mueller S; Nahon P; Rausch V; Peccerella T; Silva I; Yagmur E; Straub BK; Lackner C; Seitz HK; Rufat P; Sutton A; Bantel H; Longerich T
    Hepatology; 2017 Jul; 66(1):96-107. PubMed ID: 28170108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptotic and anti-apoptotic seromarkers for assessment of disease severity of non-alcoholic steatohepatitis.
    El Bassat H; Ziada DH; Hasby EA; Nagy H; Abo Ryia MH
    Arab J Gastroenterol; 2014 Mar; 15(1):6-11. PubMed ID: 24630506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.
    Zhang H; Rios RS; Boursier J; Anty R; Chan WK; George J; Yilmaz Y; Wong VW; Fan J; Dufour JF; Papatheodoridis G; Chen L; Schattenberg JM; Shi J; Xu L; Wong GL; Lange NF; Papatheodoridi M; Mi Y; Zhou Y; Byrne CD; Targher G; Feng G; Zheng M
    Chin Med J (Engl); 2023 Feb; 136(3):341-350. PubMed ID: 36848175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS).
    Hossain N; Stepanova M; Afendy A; Nader F; Younossi Y; Rafiq N; Goodman Z; Younossi ZM
    Scand J Gastroenterol; 2011 Apr; 46(4):479-84. PubMed ID: 21114431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obstructive Sleep Apnea Is Associated with Nonalcoholic Steatohepatitis and Advanced Liver Histology.
    Corey KE; Misdraji J; Gelrud L; King LY; Zheng H; Malhotra A; Chung RT
    Dig Dis Sci; 2015 Aug; 60(8):2523-8. PubMed ID: 25840922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.
    Younossi ZM; Page S; Rafiq N; Birerdinc A; Stepanova M; Hossain N; Afendy A; Younoszai Z; Goodman Z; Baranova A
    Obes Surg; 2011 Apr; 21(4):431-9. PubMed ID: 20532833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
    Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.